Replies to post #3197 on Jiangbo Pharmaceuticals, Inc.(fka JGBO)

[peewee]

ok then 9 mill...but that doesnt answer my other question ! :)
As i read it they are all 5 in development stage yet..so maybe they already have progress with each !
5+5=10 which i do not expect because one or two could also fail..normal in that business...
But still we are undervalued and have + 5 coming drugs in the drawer !

And number 5 of the 5 existing just started going into sales stadium !!!!

[Long-vestor]

Not exactly john.. That was 10 million in loan share placement and 5 million in shares sold, both to Pope.. Then last Octobers financials said about 4 mil in cash holdings, 10 million of cash worth was paid to past due shareholders accounting for lowered cash assets.

The 10 million from Pope was paid not for drugs but universities, their research and development for new drugs to be patented, basically first right of patent purchase.. This amount was said to be spread out within six university type drug development centers and we are unsure as of yet whether 10 or the whole 15 million was used to finance these things. ..

So when a new product or technology comes mature, GTEC has
the priority to purchase at a relatively lower price, which gives GTEC a competitive advantage compared to its peers.

Here is the list of these research institutes.


1. The Institute of Microbiology, Chinese Academy of Sciences
2. Pharmaceutical Institute of Shandong University
3. Jiangsu Nanfeng Research Center
4. Chinese Traditional Medicine Institute
5. Shandong Chinese Traditional Medicine Technical School
6. Institute for Drug Control departments

But ya'll are leaving out many, many different things like advertising just to name one.. Millions was spent on regular produced drugs and extra promoting the new chewable tablets. \ The company is investing in its future, your future and what the future brings is unknown. It is expect to be bright though. And especially by having spend this money here:

Nationwide Marketing and Distribution Network – Genesis’s extensive sales network of 1,060 actively promotes its products to hospitals, distributors and pharmacies throughout China . Direct marketing and coordinated product packaging has led to brand awareness among consumers their buying new Company products on the basis of the Company’s name.

Except, when considering the financial profile ya’ll are not including too: the CEO did say last October’s earnings were 8 million.
Take that and without growth you've got an earnings report this February of 24 million in revenues, which equates to the largest percentage increase in overall quarterly growth..

Add in expected earnings from the chewable tables, and it’s very likely to exceed the CEO’s forecast of over 100 million in revenue for 2008.. not to leave out, that; GTEC’s year ends June 2008, February’s earnings report will be mid term.

If the CEO will meet his forecast, this reporting period ought to be one heck of a good one,, exceeding 25-30 million.. However, a plain 24 million is just fine this quarter.